What changes when we fulfil the dream of living longer?
mehr
Storys zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
mehrJohnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress
London (ots/PRNewswire) - Next-generation laser vision correction provides next-day results and recovery1,2 - The next-generation ELITATM Femtosecond Laser to correct myopia with the new SILK procedure** - The latest innovation in extended depth of focus (EDOF) intraocular lenses (IOLs) will be shared with invited ...
mehrHuma collaborates with Google Cloud to improve healthcare through generative AI
New York (ots/PRNewswire) - - Huma aims to further support patients and the healthcare workforce by enhancing its regulated Software as Medical Device (SaMD) platform with the addition of generative AI applications - Huma is leveraging Google Cloud's Vertex AI platform and exploring the use of other Google GenAI tools such as Med-PaLM 2 - Huma and Google Cloud are ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehr
CartiHeal Announces First Commercial Implantation of Agili-C™ in the US
Kfar Saba, Israel (ots/PRNewswire) - CartiHeal Ltd., developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of Agili-C in the US by Dr. Ken Zaslav, a specialist in Orthopedic Surgery and Sports Medicine at Northwell Health in New York City, NY. The ...
mehrREVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL
Barcelona, Spain (ots/PRNewswire) - - HER2DX® pCR-score was significantly associated with pathological complete response in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab, with or without chemotherapy. - HER2DX® risk-score identified 85% of patients with an invasive disease event as ...
mehrHuma receives multi-condition US FDA 510(k) Class II regulatory clearance for its configurable SaMD disease management platform
New York and London (ots/PRNewswire) - - Class II clearance expands the patient population that can be managed - Companies working with Huma's platform can now launch algorithm innovations more quickly in a compliant and de-risked manner, democratising digital health innovation across the industry - Clearance was ...
mehrDEBIOPHARM SHARES ONCOLOGY PROGRAM UPDATES AT ASCO 2023 FOR NOVEL WEE1 INHIBITOR, AND FIRST-IN-CLASS CA IX THERANOSTIC APPROACH
Lausanne, Switzerland (ots) - - Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference - A poster presentation and discussion will cover promising interim results with Debio 0123, a potent, highly ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Mosquitoes prefer cooler temperatures
Bern (ots) - Mosquitoes have thermal preferences. This is an important parameter to better predict outbreaks of diseases transmitted by these insects. "If they have a choice, when it's hot, mosquitoes hide in a cool place to rest," says Niels Verhulst, author of a study recently published in the journal Thermal Biology (*). The entomologist from the University of Zurich summarises the results of the experiment he ...
mehr
Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
mehrDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
The Covid-19 pandemic is preparing us for future crises
Bern (ots) - The SNSF Corona Research Conference shows how the Covid-19 pandemic has enabled us to accumulate knowledge that will be useful in dealing with future crises. "If we ever have to deal with a new pandemic in future we will not be starting from scratch, as was the case when we were confronted with the coronavirus." These are the words of scientist Barbara Rath. As an active participant in the Vienna Vaccine ...
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehrHuma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis
New York and London (ots/PRNewswire) - - Project aims to improve patient outcomes through better clinical management of disease exacerbations using self-reported data - Exciting opportunity to improve education and empowerment and for patients to be active participants in their own care - Huma's EU MDR Class IIb ...
mehrInternational Society of Nephrology (ISN)
INTERNATIONAL SOCIETY OF NEPHROLOGY LAUNCHES GLOBAL KIDNEY HEALTH REPORT THAT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE
Brussels (ots/PRNewswire) - Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health ...
mehr
ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test
Paris and Milan (ots/PRNewswire) - - An estimated 2.3% of the European population is affected by bipolar disorder (BD)[1], a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis[2] - To date, the diagnosis of BD is based on a psychiatric clinical ...
mehrHuma receives world's first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform
New York and London (ots/PRNewswire) - - Huma's platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health innovation across the industry - Class IIb certification expands the patient population and level of disease severity that ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrFDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health / Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population
mehrREVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY
Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...
mehr
Medison Pharma; Alnylam Pharmaceuticals
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...
mehrServier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio
Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop ...
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Brain scans of people with MS help us understand the effects of Covid
Bern (ots) - People affected by multiple sclerosis need to undergo regular MRI brain scans. The images are now being used to visualise the effects of a coronavirus infection. Brain fog, memory problems, loss of the sense of smell - Covid-19 affects the brain in a number of ways, yet the mechanisms behind this remain largely unknown. This is because disease-related changes in our brains are almost impossible to detect if ...
mehrServier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
A quiet crisis manager
mehr
Vorherige12345678910Nächste